Regorafenib Induced Toxic Erythema of Chemotherapy Presenting as Malignant Intertigo with Hand Foot Skin Reaction
Clinical Dermatology Open Access Journal · 2017
DOI: 10.23880/cdoaj-16000134 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Dermatology Open Access Journal, 2017. Verfasst von Mehta Ambalal S.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Newer chemotherapeutic drugs often present with adverse reactions involving the skin.These reactions may be mistaken for infections, drug allergies or GVHD.Regorafenib is a multikinase inhibitor with a characteristic adverse event profile affecting the hands and feet as well as flexures.Because of a very high incidence of these reactions, adequate precautions to prevent, as well as early diagnosis and management, improve quality of life as well as outcomes of treatment.
Zitieren
APA
S, M. A. (2017). Regorafenib Induced Toxic Erythema of Chemotherapy Presenting as Malignant Intertigo with Hand Foot Skin Reaction. Clinical Dermatology Open Access Journal. https://doi.org/10.23880/cdoaj-16000134
Vancouver
S MA. Regorafenib Induced Toxic Erythema of Chemotherapy Presenting as Malignant Intertigo with Hand Foot Skin Reaction. Clinical Dermatology Open Access Journal. 2017. doi:10.23880/cdoaj-16000134
BibTeX
@article{S2017,
author = {S, Mehta Ambalal},
title = {Regorafenib Induced Toxic Erythema of Chemotherapy Presenting as Malignant Intertigo with Hand Foot Skin Reaction},
journal = {Clinical Dermatology Open Access Journal},
year = {2017},
doi = {10.23880/cdoaj-16000134}
}
EUVIMED